The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred.
Intellia Therapeutics (NTLA) stock plummets after the company's Q3 updates indicate a patient deeath in a Phase 3 for its nex ...
The WEF report highlights how AI and emerging technologies can revolutionize agriculture, citing impactful case studies from ...
WEF report highlights how AI, robotics, and nanotech are transforming agriculture, citing case studies from India. Read more!
The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...
Biopharmaceuticals: Redefining the Future of Modern MedicineThe Global Bio Pharmaceuticals Market is valued at USD 421.58 ...
Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.
Delhi MP Praveen Khandelwal urged PM Modi to fast-track approval and create a policy for treating LAMA2-CMD, a rare ...
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on ...
Interesting Engineering on MSN
New plant system triggers crops to grow themselves with genetic upgrades
Graduate student Arjun Ojha Kshetry and colleagues combined two key genes: WIND1, which reprograms cells near a wound, and ...
The UK regulator is creating a new framework for how it will approve rare disease treatments, which it intends to publish in ...
Awaiting FDA clinical hold letter on MAGNITUDE and MAGNITUDE-2 clinical trials of nex-zPresenting longer-term Phase 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback